Lim, Lee-Ling http://orcid.org/0000-0002-6214-6924
Chow, Elaine http://orcid.org/0000-0002-4147-3387
Chan, Juliana C. N. http://orcid.org/0000-0003-1325-1194
Article History
Accepted: 27 October 2022
First Online: 29 November 2022
Competing interests
: L.L.L. reported receiving research grants through her affiliated institutions, honoraria for consultancy and speaker fees from Abbott, AstraZeneca, Boehringer Ingelheim, Merck Sharp & Dohme, Novo Nordisk, Roche, Sanofi, Servier and Zuellig Pharma. E.C. has received speaker fees and/or institutional research support from Hua Medicine, Medtronic, Novartis and Sanofi. J.C.N.C. reported receiving research grants through her affiliated institutions, honoraria and speaker fees from Applied Therapeutics, AstraZeneca, Bayer, Boehringer Ingelheim, Celltrion, Hua Medicine, Lee Powder, Lilly, Merck Sharpe Dohme, Merck Serono, Pfizer, Sanofi, Servier and Viatris Pharmaceutical; she holds patents of genetic markers for predicting diabetes and its complications; she is a co-founder of a biotechnology start-up company, GemVCare, with partial support from the Hong Kong Government Innovation and Technology Commission to provide precision diabetes care, and is Chief Executive Officer of Asia Diabetes Foundation on a pro bono basis.